Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 14, Issue 6, 2015, Pages 755-762

  Waters, Valerie J ^a   Stanojevic, Sanja ^a   Sonneveld, Nicole ^a   Klingel, Michelle ^a   Grasemann, Hartmut ^a   Yau, Yvonne C W ^a   Tullis, Elizabeth ^b   Wilcox, Pearce ^c   Freitag, Andreas ^d   Chilvers, Mark ^e   Ratjen, Felix A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Antibiotics; Cystic fibrosis; Inflammation; Pulmonary exacerbations

Indexed keywords

C REACTIVE PROTEIN; CEFTAZIDIME; LEUKOCYTE ELASTASE; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BIOFILM; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DENSITY; DISEASE EXACERBATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; MALE; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SERUM; SPUTUM; TREATMENT RESPONSE; ADOLESCENT; CHILD; COMPLICATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; LUNG DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG DISEASES; MALE; YOUNG ADULT;

EID: 84941113284     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.01.007     Document Type: Article

References (30)

1. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153(4):345-352.
2. Waters V., Stanojevic S., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012, 40(1):61-66.
3. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182(5):627-632.
4. Waters V., Atenafu E.G., Salazar J.G., Lu A., Yau Y., Matukas L., et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012, 11(1):8-13.
5. de Boer K.V.K., Tullis E., Doucette S., Fergusson D., Freitag A., Paterson N., et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011, 66(8):680-685.
6. Parkins M.D., Rendall J.C., Elborn J.S. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012, 141(2):485-493.
7. Ordonez C.L., Henig N.R., Mayer-Hamblett N., Accurso F.J., Burns J.L., Chmiel J.F., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(12):1471-1475.
8. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis. Am J Respir Crit Care Med 2007, 175(8):822-828.
9. Yau Y.C., Ratjen F., Tullis E., Wilcox P., Freitag A., Chilvers M., et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros 2015, 14(2):262-266.
10. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
11. Moskowitz S.M., Emerson J.C., McNamara S., Shell R.D., Orenstein D.M., Rosenbluth D., et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011, 46(2):184-192.
12. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
13. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338.
14. Quanjer P.H., Stanojevic S., Cole T.J., Baur X., Hall G.L., Culver B.H., et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012, 40(6):1324-1343.
15. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1425-1431.
16. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27(1):158-163.
17. Sanders D.B., Hoffman L.R., Emerson J., Gibson R.L., Rosenfeld M., Redding G.J., et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010, 45(2):127-134.
18. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141(4 Pt 1):914-921.
19. Wojewodka G., De Sanctis J.B., Bernier J., Berube J., Ahlgren H.G., Gruber J., et al. Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS One 2014, 9(2):e88567.
20. Nick J.A., Sanders L.A., Ickes B., Briones N.J., Caceres S.M., Malcolm K.C., et al. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax 2013, 68(10):929-937.
21. Shoki A.H., Mayer-Hamblett N., Wilcox P.G., Sin D.D., Quon B.S. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013, 144(5):1659-1670.
22. Sagel S.D., Wagner B.D., Anthony M.M., Emmett P., Zemanick E.T. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012, 186(9):857-865.
23. Sly P.D., Gangell C.L., Chen L., Ware R.S., Ranganathan S., Mott L.S., et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013, 368(21):1963-1970.
24. McElvaney N.G., Hubbard R.C., Birrer P., Chernick M.S., Caplan D.B., Frank M.M., et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991, 337(8738):392-394.
25. Martin S.L., Downey D., Bilton D., Keogan M.T., Edgar J., Elborn J.S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006, 41(2):177-183.
26. Parrillo J.E., Fauci A.S. Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol 1979, 19:179-201.
27. Cheng K., Ashby D., Smyth R.L. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev 2013, 6. CD000407.
28. Dovey M., Aitken M.L., Emerson J., McNamara S., Waltz D.A., Gibson R.L. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007, 132(4):1212-1218.
29. Lands L.C., Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev 2013, 6. CD001505.
30. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756.